Neurocrine Biosciences, Inc. (NBIX)
Company Info
| ISIN | US64125C1099 |
|---|---|
| CUSIP | 64125C109 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| IPO Date | May 23, 1996 |
Highlights
| Market Cap | $12.86B |
|---|---|
| EPS (TTM) | $3.75 |
| PE Ratio | 33.87 |
| PEG Ratio | 0.30 |
| Total Revenue (TTM) | $2.24B |
| Gross Profit (TTM) | $2.20B |
| EBITDA (TTM) | $614.00M |
| Year Range | $107.84 - $157.98 |
| Target Price | $162.96 |
| Short % | 3.03% |
| Short Ratio | 3.19 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: NBIX vs. VOO, NBIX vs. DHR, NBIX vs. SPY, NBIX vs. MSFT, NBIX vs. KNSL, NBIX vs. UTHR, NBIX vs. BMRN, NBIX vs. HIMS, NBIX vs. ABT, NBIX vs. BMY
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Neurocrine Biosciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Neurocrine Biosciences, Inc. had a return of -4.74% year-to-date (YTD) and 11.68% in the last 12 months. Over the past 10 years, Neurocrine Biosciences, Inc. had an annualized return of 20.88%, outperforming the S&P 500 benchmark which had an annualized return of 11.39%.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -4.74% | 25.48% |
| 1 month | 7.79% | 2.14% |
| 6 months | -11.61% | 12.76% |
| 1 year | 11.68% | 33.14% |
| 5 years (annualized) | 2.12% | 13.96% |
| 10 years (annualized) | 20.88% | 11.39% |
Monthly Returns
The table below presents the monthly returns of NBIX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 6.08% | -6.70% | 5.77% | -0.28% | -1.55% | 1.67% | 2.83% | -10.25% | -9.32% | 4.38% | -4.74% | ||
| 2023 | -7.12% | -7.06% | -1.82% | -0.18% | -11.39% | 5.33% | 8.05% | 6.87% | 3.32% | -1.39% | 5.09% | 13.01% | 10.31% |
| 2022 | -7.22% | 13.73% | 4.32% | -3.97% | 3.84% | 4.27% | -3.44% | 11.15% | 1.51% | 8.39% | 10.37% | -6.00% | 40.24% |
| 2021 | 14.50% | -0.22% | -11.20% | -2.84% | 1.83% | 1.14% | -4.22% | 2.13% | 0.75% | 9.91% | -21.02% | 2.31% | -11.14% |
| 2020 | -6.89% | -5.38% | -8.61% | 13.39% | 27.12% | -2.21% | -1.34% | -3.27% | -17.40% | 2.61% | -3.78% | 0.96% | -10.83% |
| 2019 | 23.54% | -12.43% | 14.05% | -18.00% | 17.36% | -0.41% | 14.17% | 3.14% | -9.36% | 10.41% | 17.21% | -7.82% | 50.53% |
| 2018 | 10.16% | -1.22% | -1.78% | -2.23% | 18.72% | 2.06% | 2.29% | 22.35% | 0.00% | -12.85% | -17.62% | -19.10% | -7.96% |
| 2017 | 10.88% | 2.91% | -1.95% | 23.33% | -18.60% | 5.82% | 4.41% | 17.84% | 8.27% | 1.35% | 15.75% | 7.93% | 100.49% |
| 2016 | -24.78% | -13.56% | 7.53% | 15.25% | 8.93% | -8.46% | 10.52% | -3.52% | 4.50% | -13.57% | 6.12% | -16.68% | -31.59% |
| 2015 | 50.67% | 16.01% | 1.69% | -14.15% | 28.66% | 8.89% | 4.94% | -7.46% | -14.21% | 23.37% | 10.76% | 4.05% | 153.22% |
| 2014 | 82.98% | 3.16% | -8.68% | -12.92% | -0.93% | 6.80% | -8.46% | 20.10% | -3.92% | 18.19% | 7.61% | 12.09% | 139.19% |
| 2013 | 21.12% | 16.78% | 14.89% | -5.06% | 12.05% | 3.48% | 4.56% | 4.15% | -22.31% | -16.70% | 4.14% | -4.89% | 24.87% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of NBIX is 53, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Neurocrine Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Neurocrine Biosciences, Inc. was 97.21%, occurring on Nov 12, 2009. Recovery took 2007 trading sessions.
The current Neurocrine Biosciences, Inc. drawdown is 18.05%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.21% | Mar 16, 2006 | 924 | Nov 12, 2009 | 2007 | Nov 2, 2017 | 2931 |
| -70.28% | Feb 27, 1997 | 605 | Jul 22, 1999 | 86 | Nov 22, 1999 | 691 |
| -66.16% | Mar 6, 2000 | 257 | Mar 12, 2001 | 173 | Nov 20, 2001 | 430 |
| -54.12% | Dec 26, 2001 | 135 | Jul 10, 2002 | 228 | Jun 5, 2003 | 363 |
| -50.71% | Apr 28, 2004 | 255 | May 2, 2005 | 207 | Feb 27, 2006 | 462 |
Volatility
Volatility Chart
The current Neurocrine Biosciences, Inc. volatility is 9.16%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Neurocrine Biosciences, Inc. compared to its peers in the Drug Manufacturers - Specialty & Generic industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for NBIX in comparison to other companies of the Drug Manufacturers - Specialty & Generic industry. Currently, NBIX has a PE value of 33.9. This PE ratio falls in the average range for the industry.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for NBIX in comparison to other companies of the Drug Manufacturers - Specialty & Generic industry. Currently, NBIX has a PEG value of 0.3. This PEG ratio falls in the average range for the industry.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Neurocrine Biosciences, Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |